Close Menu

NEW YORK (GenomeWeb) – Quanterix today announced a strategic investment in ImmunArray, a move that could strengthen each company's efforts in addressing neurodegenerative disease diagnostics.

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will gain access to ImmunArray's biomarker portfolio for traumatic brain injury and add select biomarkers to its multiplex panel for neurology research. ImmunArray, based in both Israel and Virginia, will in turn gain access to Quantertix's Simoa single-molecule array technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.

Jun
17
Sponsored by
Illumina

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.